Department of Oncologic & Digestive Surgery, AP-HP, Hospital Lariboisière, 2 Rue Ambroise Paré, 75475, Paris Cedex 10, France.
Université Paris Diderot, Sorbonne Paris Cité, CART, INSERM U965, 74575, Paris, France.
Surg Endosc. 2020 May;34(5):2040-2049. doi: 10.1007/s00464-019-06984-8. Epub 2019 Jul 18.
The outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) depends on the extent of peritoneal metastases (PM) and the completeness of cytoreduction (CCR). The role of preoperative assessment of PM is to identify potential candidates for CRS/HIPEC and to prevent unwarranted laparotomy for those who are not. Laparoscopy has been utilized for that purpose but with concerns related to technical difficulties and risk of trocar site metastases. Single-incision laparoscopic peritoneal exploration (SILPE) has not yet been evaluated in this setting.
This single-center retrospective study examined patients from January 2011 to December 2015 who underwent SILPE for diagnosis and staging of PM. Preoperative, intraoperative, and postoperative data were collected. For the patients who underwent subsequent laparotomy, a comparison between SILPE and laparotomy findings was made.
A total of 183 SILPE were performed. Primary sites were mostly colorectal in 72 cases (39.3%) and gastric in 47 (25.7%). Overall, 157 patients (85.8%) had at least one prior abdominal surgery and 48 (26.2%) had 3 or more. SILPE was successfully achieved in 90.2% of the cases. Two (1.2%) intraoperative complications and five (3%) postoperative complications were observed. Eighty-one patients had laparotomy, with a median of 27 days between SILPE and laparotomy (4-162 days). The peritoneal carcinomatosis index PCI was 9.7 ± 7.5 at SILPE, and 13.5 ± 9.6 at laparotomy. The positive predictive value of SILPE to predict CCR was 79.5%. SILPE sensitivity was 75% and specificity 97%. The lowest sensitivity was in regions 9-12 ranging from 44 to 53%.
SILPE can be safely incorporated in the management of patients with PM. It is a safe and feasible staging tool, allowing for preventing unwarranted laparotomy for patients not deemed candidate for CRS/HIPEC. Even though it may underestimate PCI, SILPE accurately predicts the possibility of CCR.
细胞减灭术和腹腔热灌注化疗(CRS/HIPEC)的结果取决于腹膜转移(PM)的程度和细胞减灭术的完全程度(CCR)。PM 的术前评估的作用是确定 CRS/HIPEC 的潜在候选者,并防止对那些不适合的患者进行不必要的剖腹手术。腹腔镜已被用于此目的,但存在与技术困难和trocar 部位转移相关的风险。单切口腹腔镜腹膜探查(SILPE)尚未在这种情况下进行评估。
本单中心回顾性研究检查了 2011 年 1 月至 2015 年 12 月期间接受 SILPE 诊断和分期 PM 的患者。收集了术前、术中及术后的数据。对于随后接受剖腹手术的患者,对 SILPE 和剖腹手术的结果进行了比较。
共进行了 183 例 SILPE。原发部位主要为结直肠 72 例(39.3%)和胃 47 例(25.7%)。总体而言,157 例(85.8%)患者至少有一次既往腹部手术,48 例(26.2%)有 3 次或更多。90.2%的病例成功完成 SILPE。观察到 2 例(1.2%)术中并发症和 5 例(3%)术后并发症。81 例患者行剖腹手术,SILPE 与剖腹手术之间的中位时间为 27 天(4-162 天)。SILPE 时的腹膜癌病指数(PCI)为 9.7±7.5,剖腹手术时为 13.5±9.6。SILPE 预测 CCR 的阳性预测值为 79.5%。SILPE 的灵敏度为 75%,特异性为 97%。灵敏度最低的区域为 9-12 区,范围为 44%至 53%。
SILPE 可安全应用于 PM 患者的治疗。它是一种安全可行的分期工具,可避免对不适合 CRS/HIPEC 的患者进行不必要的剖腹手术。尽管它可能低估了 PCI,但 SILPE 能准确预测 CCR 的可能性。